• About Us
    • About AJMC
    • About AJPB
  • Publications
    • AJMC
    • AJPB
    • Evidence-Based Diabetes Management
    • Evidence-Based Oncology
    • Supplements
    • Subscribe for FREE
  • AJMC TV
    • Interviews
    • Peer Exchange
  • Interactive
    • Interactive Tools
    • Featured Podcasts
  • Conferences
    • ACC 2013
    • AJMC Live Meeting - Oncology
    • AES2012
    • AHIP 2012
    • AHIP 2012 Fall Forum
    • AHIP Medicare Medicaid
    • AMCP Fall 2012
    • AMCP Spring 2013
    • ADA 2012
    • ASH 2012
    • CHEST 2012
    • Joslin Diabetes Innovation
    • NAMCP 2012
    • NAMCP Spring 2013
    • SCAI 2013
    • ATS 2013
  • News
  • Info for Authors
    • Information for Authors
    • Call for Papers
    • Submit / Track a Manuscript
    • Authorship Forms
    • Information for Reviewers
  • Resource Centers
    • Acute Coronary Syndrome
    • Biosimilars
    • Care Management
    • Diabetes
    • Evidence-Based Oncology
    • Pain
    • Value-Based Cardiology
    • Value-Based Insurance Design
AJMC.com - Managed Markets Network
Advertisement
Supplement
Archives
Issue:
Express Report - New Directions and Options for the Management of Hypertension
Volume:
12
Number:
1 Express
SUPPLEMENT CONTENT
Introduction
New Direct Renin Inhibitor as Monotherapy or in Combination with Hydrochlorothiazide Controls Blood Pressure
Valsartan Reduces Inflammatory Marker Associated with Hypertensive and Comorbid Risk; Effect Neutralized by Thiazide Diuretic
The Impact of Fixed-dose Combinations on Blood Pressure Control, Persistence, and Comorbid Disease
Ability to Control Blood Pressure and Choice of Antihypertensive Impact Development and Course of Comorbid Disease
Initial Drug Choice and Economics Affect Healthcare Utilization and Persistence
Advertisement
Advertisement
Advertisement
About Us | Contact Us | Advertise | Terms & Conditions | Press Room | Copyright HCPLive 2006-2013 | Intellisphere, LLC. All Rights Reserved.
Partner Websites: Pharmacy Times | Targeted Therapies | PainLive | HCPLive | ONCLive